Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I.
Patients with multiple endocrine neoplasia (MEN) type I underwent pancreatic surgery at presymptomatic (n = 8, mean age 33 years) or symptomatic (n = 12, mean age 51 years) stages of pancreatic endocrine involvement with the principal aim to evaluate postoperative morbidity, survival, and malignant potential of the pancreatic lesion. Radiologic signs of malignancy were not identified in any patient prior to exploration. All patients displayed multiple tumors with generally complex immunoreactivity. Normal postoperative pancreatic tumor markers were recorded in five of the asymptomatic patients, which became abnormal in three of them at a mean of 3 years after surgery. All patients remained without symptoms for a mean of 6 years after operation. In four symptomatic individuals (33%) metastases were identified at exploration, and two died with tumor; 83% of symptomatic patients displayed persistent or recurrent endocrine morbidity from the pancreatic lesion. Recognizing lead time bias, this limited and uncontrolled patient comparison suggests that exploration at the symptomatic stage of pancreatic involvement in MEN-I patients is unsatisfactory. Rather than to obtain biochemical cure, surgery in asymptomatic patients might be regarded as a means of cancer prevention. The malignancy of the pancreatic lesion may be preceded by several decades of biochemical abnormality. Extensive screening for this lesion allows diagnosis during adolescence and the timely application of primary exploration. Active management of individuals with repeated biochemical analyses followed by selective reintervention could enable satisfactorily maintained pancreatic functions and substantial duration of cancer prevention.
Skogseid
B
B
Department of Internal Medicine, University Hospital, S-751 85 Uppsala, Sweden.
Oberg
K
K
Eriksson
B
B
Juhlin
C
C
Granberg
D
D
Akerström
G
G
Rastad
J
J
D000236:Adenoma / Q000097:blood / Q000601:surgery; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis; D002471:Cell Transformation, Neoplastic; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000601:surgery; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000097:blood / Q000601:surgery*; D010180:Pancreatectomy / Q000009:adverse effects; D010190:Pancreatic Neoplasms / Q000097:blood / Q000517:prevention & control / Q000601:surgery*; D010191:Pancreatic Polypeptide / Q000097:blood; D011183:Postoperative Complications; D015996:Survival Rate; D015043:Zollinger-Ellison Syndrome / Q000097:blood / Q000601:surgery
D014408:Biomarkers, Tumor; D053379:Chromogranin A; D002864:Chromogranins; D010191:Pancreatic Polypeptide